Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of GSK quadrivalent influenza vaccine lot consistency and immunogenicity in adults
2010-021034-63Phase 3Completed
- Sponsor
- GSK
- Start
- Jul 2010
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of Fluarix Quadrivalent, Fluarix and TIV-2 in influenza (5 arms), sponsored by GSK. Primary endpoint: Humoral immune response based on hemagglutination inhibition antibodies. Started Jul 2010; status: completed.
02
Drugs
Fluarix QuadrivalentFluarixTIV-2
03
Conditions
influenza
Beyond the preview
Go deeper on 2010-021034-63.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021034-63.